Hikma appoints Umang Vohra as a Director

Hikma appoints Umang Vohra as a Director

London, 9 November 2026 - Hikma Pharmaceuticals PLC (Hikma) announces the appointment of Umang Vohra as an independent Non-Executive Director with effect from 1 December 2026. Umang will also be appointed a member of the Audit Committee and Nomination and Governance Committee with effect from 1 December 2026.

Commenting on the appointment, Victoria Hull, Chair said “I am delighted to welcome Umang to the Hikma Board. Umang is an experienced CEO with deep knowledge of the generic pharmaceutical market and an impressive track record in growth, innovation, portfolio development and transformation. His extensive international experience, particularly in North America, will bring valuable perspective to the Board.”

About Umang Vohra

Umang currently serves as Chair and Chief Executive Officer of Cohance Lifesciences Limited, an end-to-end innovation-led CDMO business listed in India. In this role he divides his time between the US and India.

Umang is also an independent board member of AGS Health, a revenue cycle management company registered in India.

Umang previously served as CEO of Cipla Limited and is credited with transforming Cipla into a diversified global pharmaceutical enterprise. Earlier in his career, Umang held senior finance, business development and operational leadership roles at Dr. Reddy’s Laboratories Limited, including as CFO and Head of its North American business.

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal: EVP, Strategic Planning and Global Affairs +44 (0) 20 7399 2760

Helen Middlemist, Group Company Secretary +44 (0) 20 7399 2760

This announcement is made in accordance with Listing Rule 6.4.6. There is no further information to be disclosed under the requirements of Listing Rule 6.4.8 of the Listing Rules in relation to Umang Vohra’s appointment.

About Hikma:

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)